Iranian scientists have developed a radiopharmaceutical for targeted treatment of neuroendocrine tumors, in another great step in the country’s efforts to use nuclear technology to promote medical science.
Rhenium-188 can be used in treating cancer developing neuroendocrine cells that have characteristics similar to nerve cells and hormone-producing cells.
Neuroendocrine tumors are rare and can develop anywhere in the body.
Most of the tumors arise in the lungs, appendix, small intestine, rectum, and pancreas.
Using the radiopharmaceutical, it is possible to diagnose and the treatment of neuroendocrine tumors and the resulting metastases will be provided to patients in the early stages of the disease.
In a hard-fought encounter, Iran’s national football team defeated Kyrgyzstan 3-2, maintaining their undefeated streak…
A major fire broke out in a chemical warehouse on Naser Khosrow Street in southern…
Syrian Foreign Minister Bassam al-Sabbagh, during a joint press conference with his Iranian counterpart in…
Russian President Vladimir Putin on Tuesday approved an updated nuclear doctrine, Reuters reported citing the…
Tehran has strongly condemned the new sanctions of the European Union and the United Kingdom…
Jomhouri-e Eslami, an Iranian newspaper known for its sharp critiques, has scolded Iran’s officials for…